GLP-1 Receptor Agonist Use Linked to Reduced Risks for Substance Use Disorder

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on March 9, 2026.

via HealthDay

MONDAY, March 9, 2026 -- The use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with reduced risks for developing substance use disorders (SUDs), according to a study published online March 4 in The BMJ.

Miao Cai, Ph.D., from the VA Saint Louis Health Care System, and colleagues examined whether initiation of GLP-1 receptor agonists is associated with a reduced risk for incident SUDs in people with no history of SUD (protocol 1) or with a reduced risk for SUD-related adverse clinical outcomes among people with a preexisting SUD (protocol 2). Seven trials were included for each incident SUD outcome (protocol 1), and one trial was included for adverse outcomes in people with preexisting SUD (protocol 2).

The primary trial of protocol 1 included 524,817 initiators of GLP-1 receptor agonists or sodium-glucose cotransporter-2 (SGLT-2) inhibitors (124,001 and 400,816, respectively). Protocol 2 included 16,768 GLP-1 receptor agonist initiators and 64,849 SGLT-2 inhibitor initiators. The researchers found that GLP-1 receptor agonist initiation was associated with a reduced risk for disorders related to alcohol use, cannabis use, cocaine use, nicotine use, opioid use, and other SUDs compared with initiation of SGLT-2 inhibitors (hazard ratios, 0.82, 0.86, 0.80, 0.80, 0.75, and 0.87, respectively) and with a reduced risk for the composite outcome of all incident SUDs (hazard ratio, 0.86). GLP-1 receptor agonist initiation was associated with a reduced risk for SUD-related emergency department visits, SUD-related hospital admissions, SUD-related mortality, drug overdose, and suicidal ideation or attempt (hazard ratios, 0.69, 0.74, 0.50, 0.61, and 0.75, respectively) among people with preexisting SUDs.

"Our results show that GLP1 receptor agonist-related agonism may prevent addiction phenotypes across all major drug classes," the authors write.

One author disclosed ties to Pfizer.

Abstract/Full Text

Editorial

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-03-10 01:46

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords